The BAZ2A Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the BAZ2A gene has been disrupted to create a loss-of-function model for advanced biomedical research. This product provides a heterogeneous pool of edited cells carrying diverse BAZ2A-targeting events, enabling robust functional studies without single-cell cloning. BAZ2A encodes the bromodomain adjacent to zinc finger domain protein 2A, a scaffold component of the nucleolar remodeling complex (NoRC) that mediates epigenetic silencing of ribosomal DNA (rDNA). By eliminating BAZ2A expression, this model facilitates interrogation of rDNA transcription regulation, heterochromatin formation, and nucleolar organization in a human cell context.
The host cell line, HAP1, is a near-haploid derivative of the KBM-7 chronic myeloid leukemia (CML) cell line and exhibits an adherent, fibroblast-like morphology with a male karyotype. Its near-haploid genome minimizes genetic redundancy and simplifies the interpretation of knockout phenotypes, making HAP1 an ideal platform for functional genomic screens, gene essentiality studies, and mechanistic dissection of tumor-related pathways. Derived from a CML background, HAP1 retains features relevant to hematological malignancy research while offering the practical advantages of single-copy genetics for unambiguous genotype-phenotype correlations.
BAZ2A functions as a central scaffold within the NoRC complex, where it interacts with SMARCA5 (SNF2H), the transcription termination factor TTF-I, and multiple epigenetic effectors including HDAC1, DNMT1, DNMT3B, HP1, and methyl-CpG-binding domain protein MBD2. Through its bromodomain, BAZ2A binds acetylated histones and recruits histone deacetylases and DNA methyltransferases to rDNA repeats, facilitating de novo DNA methylation and repressive histone modifications that establish a silent chromatin state. This repressive activity is regulated by upstream signals such as the androgen receptor and the oncogenic transcription factor MYC, and it directly controls downstream targets like rDNA loci, pRNA, and the methyltransferase DNMT3B. By suppressing rDNA transcription, BAZ2A limits ribosome biogenesis and thereby influences global protein synthesis and cellular proliferation.
In the HAP1 background, disruption of BAZ2A provides a unique opportunity to examine the consequences of NoRC complex dysfunction in a simplified genetic setting. Loss of BAZ2A-mediated rDNA silencing is expected to relieve transcriptional repression of rDNA, alter nucleolar architecture, and perturb ribosome biogenesis??processes frequently dysregulated in aggressive cancers such as prostate carcinoma and hepatocellular carcinoma, as well as in certain neurodevelopmental disorders. The near-haploid nature of HAP1 facilitates clear genotype-phenotype correlations, making this polyclonal knockout population particularly suitable for dissecting the molecular dependencies of BAZ2A in CML-derived cells and for screening chemical probes that target bromodomain?Cacetylated histone interactions.
Researchers can employ these BAZ2A knockout polyclonal cells to investigate epigenetic silencing mechanisms through assays such as ChIP-qPCR profiling of histone modifications (e.g., H3K9me3, H4K20me3) at rDNA loci, RT-qPCR quantification of pre-rRNA transcripts, and immunofluorescence visualization of nucleolar disruption. The model is also well suited for functional genomics platforms including RNA-seq transcriptome profiling, loss-of-function screens, and bromodomain inhibitor sensitivity testing in cell proliferation and viability assays. By coupling genetic disruption with pharmacological inhibition, scientists can dissect BAZ2A-associated dependencies in cancer cell biology and explore its potential as a therapeutic target. For further technical details or to inquire about this product, please contact Ascent Research.
